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Abstract
Modulation of host immunity in invasive fungal infection is an appealing but as yet mostly elusive 
treatment strategy. Animal studies in invasive candidiasis and aspergillosis have demonstrated 
beneficial effects of colony stimulating factors, interferon-gamma and monoclonal antibodies. 
More recent studies transfusing leukocytes pre-loaded with lipophilic anti-fungal drugs, or 
modulated T-cells, along with novel vaccination strategies show great promise. The translation of 
immune therapies into clinical studies has been limited to date but this is changing and the results 
of new Candida vaccine trials are eagerly awaited. Immune modulation in HIV-associated mycoses 
remains complicated by the risk of immune reconstitution inflammatory syndrome and although 
exogenous interferon-gamma therapy may be beneficial in cryptococcal meningitis, early initiation 
of anti-retroviral therapy leads to increased mortality. Further study is required to better target 
protective immune responses.
INTRODUCTION
Invasive fungal infections (IFI) are an increasing global health problem, resulting in 
significant morbidity and mortality among individuals with impaired immunity [1–3]. 
Despite recent advances in the care of patients with IFI, conventional therapeutic options 
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remain limited, and outcomes poor. A potential strategy to improve this is to reverse 
underlying immune deficits, or modify and enhance host immune responses using 
immunomodulatory treatments. However, immune responses against fungal pathogens are 
diverse, and detailed understanding of the underlying immunology is essential to enable 
effective interventions. Here we review recent advances in immunomodulatory therapies for 
treatment and prevention of invasive fungal infections. A summary of the main findings is 
given in Table 1.
REMOVAL OR REVERSAL OF UNDERLYING IMMUNE SUPPRESSION
Clinical practice guidelines strongly recommend reduction or elimination of immune 
suppression in patients with invasive aspergillosis (IA) and disseminated candidiasis [4,5]. 
These recommendations are based on observational data and an understanding of the 
epidemiology and immunopathogenesis of invasive fungal disease [6]. However, in some 
patients with fungal infection this strategy may not be feasible and may also result in 
paradoxical clinical worsening. The best example of this is HIV-associated cryptococcal 
meningitis immune reconstitution inflammatory syndrome (CM-IRIS), where patients 
develop worsening meningitis following initiation of anti-retroviral therapy (ART) [7]. The 
main predisposing factor for CM-IRIS is a lack of cerebrospinal fluid (CSF) inflammation 
and increased fungal burden prior to ART initiation [8,9]. Following ART initiation, excess 
CSF antigen triggers chemokine-mediated cell trafficking, macrophage activation, and 
marked inflammation [10,11]. After two randomised controlled trials demonstrated 
increased mortality with early ART [12,13], treatment guidelines now recommend delaying 
initiation of ART until at least four weeks of antifungal treatment have been completed to 
minimise the risk of CM-IRIS [14]. IRIS is also reported among individuals with HIV 
associated Pneumocystis jirovecii, Histoplasma capsulatum, and Taralomyces marneffei 
infections[15]. Similar clinical deteriorations have also been observed in solid organ 
transplant recipients with cryptococcal meningitis who undergo rapid reductions in immune 
suppressive medications [16], and in patients with chronic disseminated candidiasis 
following neutrophil recovery [17]. Given the problems with infection following 
haematopoietic stem cell transplantation (HSCT), there are now efforts to explore novel 
conditioning strategies using haematopoetic cell-specific immunotoxins that avoid such 
profound immune suppression [18].
CYTOKINE THERAPY
A variety of pro-inflammatory cytokines have been studied to determine whether their 
administration may improve host immune response against IFIs. Given the clear association 
between neutropenia and IFIs much of this focus has been on colony stimulating factors. 
The prophylactic use of granulocyte colony stimulating factor (G-CSF) in patients with 
chemotherapy-associated neutropenia is well established and reduces overall incidence of 
infections and febrile neutropenia by almost half [19]. G-CSF stimulates neutrophil 
production, maturation, phagocytic activity and oxidative burst metabolism [20], and 
enhances protection against disseminated Aspergillus and Candida in animal models [21–
23]. In clinical practice, prophylactic G-CSF has not convincingly been shown to reduce the 
incidence of IFIs [24]. However, two small studies demonstrate a potential benefit of G-CSF 
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when used alongside anti-fungal therapy as an adjunctive treatment leading to faster 
resolution of infection compared to antifungal therapy alone [25,26].
Granulocyte-macrophage colony stimulating factor (GM-CSF) is also licenced for treatment 
of chemotherapy-associated neutropenia. It promotes the production, maturation, activation, 
and migration of neutrophils, monocytes, macrophages and lymphocytes [27], and has 
potential advantages over G-CSF due to its wider effects on the immune response [28]. 
Animal and cell culture models suggest GM-CSF is important in the host response against 
Aspergillus and Cryptococcus [29,30], and individuals with anti-GM-CSF auto-antibodies 
have been found to be at increased risk of infection with C. gattii [31]. In patients receiving 
chemotherapy for acute myeloid leukaemia and allogeneic haematological stem cell 
transplantation (HSCT), prophylactic GM-CSF results in faster neutrophil recovery, lower 
all-cause mortality, lower transplantation-related mortality, and lower invasive fungal 
disease-associated mortality [32–34]. Case reports and case series suggest GM-CSF may be 
beneficial when used alongside antifungal treatments in treating a variety of IFI, including 
candidiasis, aspergillosis, and zygomycosis [35–37].
Macrophage colony-stimulating factor (M-CSF) also rapidly increases myeloid 
differentiation of hematopoietic stem cells via activation of the myeloid regulator PU.1 [38]. 
Data from animal models suggest that M-CSF may also play a role in controlling invasive 
fungal infections [39]. However, it has never been tested in humans and unlike G-CSF and 
GM-CSF, there is no pharmaceutical product available.
Interferon-gamma (IFN-γ) is produced by NK cells and T lymphocytes and promotes 
classical activation of macrophages resulting in increased phagocytosis, production of 
reactive oxygen species and reactive nitrogen intermediates; it is a vital component of the 
host immune response against intracellular pathogens [40]. IFN-γ knockout mice and people 
with impaired IFN-γ signalling (IFN-γ receptor 1 deficiency or anti-IFN-γ autoantibodies) 
are at significantly increased risk of severe infection with C. albicans, C. neoformans, H. 
capsulatum and Coccidioides immitis [41–46]. In animal models of invasive aspergillosis, 
IFN-γ enhances neutrophil function augments the response to anti-fungal therapy resulting 
in significantly improved survival [47,48]. Improvements in neutrophil function resulting in 
significant reductions in serious infections have also been observed in patients with chronic 
granulomatous disease (CGD) treated with prophylactic IFN-γ [49].
In HIV-infected individuals with cryptococcal meningitis, low CSF concentrations of IFN-γ 
are associated with higher fungal burden, slower clearance of Cryptococcus, and increased 
mortality [50]. Animal models have demonstrated significantly improved survival when 
IFN-γ was used as an adjunctive treatment alongside amphotericin B [51], prompting two 
phase II trials of adjunctive IFN-γ in AIDS patients with cryptococcal meningitis [52,53]. 
The first showed a non-significant trend towards better CSF sterilization; the second showed 
significantly faster clearance of infection when IFN-γ was added to antifungal treatment. 
IFN-γ has also been used to augment the host immune response in cases of HIV-negative 
patients with cryptococcal meningitis, invasive aspergillosis, invasive candidiasis and 
disseminated H. capsulatum infection [54–56].
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LEUKOCYTE TRANSFUSIONS
Infusion of donor granulocytes is an experimental technique to improve survival from 
invasive fungal infections in the setting of profound neutropenia and requires harvesting of 
granulocytes from an ABO matched donor using leukophoresis. Case reports and 
retrospective case-control studies suggest granulocyte transfusions are feasible, safe and 
associated with better than expected survival rates [57–59]. However, clinical benefit has yet 
to be clearly demonstrated, and the single randomised controlled trial conducted to date 
showed no survival benefit in the setting of neutropenic sepsis [60]. In a mouse model of 
invasive aspergillosis, significant improvement in outcome was observed when granulocytes 
were loaded with the lipophilic triazole posaconazole [61].
Adoptive transfer of pathogen-specific T cells is another promising treatment strategy. 
Prolonged lymphopenia is a major risk factor for post-engraftment invasive aspergillosis 
following HSCT, and the presence of Aspergillus-specific Th1 cells is associated with 
successful resolution of infection [62–64]. Murine studies have demonstrated that adoptive 
transfer of Aspergillus-specific Th1 memory CD4 T cells (generated through exposure to 
Aspergillus culture filtrate antigens) results in prolonged survival in experimentally infected 
mice [65]. This strategy was replicated in a single small human study involving ten HSCT 
patients with pulmonary aspergillosis; reductions in serum galactomannan and a trend 
towards improved survival were seen [66].
To expedite clonal expansion, co-stimulatory molecules (CD137 and CD154) can be used to 
select antigen-specific T cells. This technique has been used to generate Aspergillus-specific 
T cells, with in vitro activity against a wide range of fungal isolates [67]. In a further 
refinement, adoptive transfer of chimeric antigen receptor (CAR) T cells targeting tumor 
antigens has been adapted to target fungal pathogens [68]. This involves fusing the 
extracellular domain of Dectin-1 to a CAR cassette and transferring into human T cells 
resulting in a modified β-1,3-glucan-specific T lymphocyte. Such cells have been shown to 
inhibit germinating Aspergillus spores in vitro, and improve outcome in experimentally 
infected mice [69]. These two techniques are clarified further in Figure 1.
An alternative approach to improving T cell responses is the use of immune checkpoint 
inhibitors targeting the inhibitory T cell co-receptors, including programmed death 1 (PD-1) 
[70]. Although mostly studied in cancer, in a murine model of Candida blood stream 
infection, PD-1 blockade improved T cell responses and survival when combined with 
fluconazole [71]. A trial of PD-1 blockade was also used successfully in a patient with 
refractory mucormycosis in combination with IFN-γ and anti-fungal therapy [72].
MONOCLONAL ANTIBODY THERAPY
Administration of monoclonal antibodies reactive with fungal cell surface components 
protects animals in models of candidiasis, aspergillosis, cryptococcosis and histoplasmosis 
[73–76]. Human trials of monoclonal antibodies directed against C. albicans heat shock 
protein 90 resulted in faster clearance of infection, and pilot studies of anti-C. neoformans 
capsule antibodies showed temporary reductions in antigen titres [77,78]. Efforts to develop 
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a monoclonal antibody with pan-fungal efficacy have shown some promise with monoclonal 
antibodies directed again β-glucans [79] and β-1,6-poly-N-acetyl-D-glucosamine [80].
VACCINATION
No fungal vaccine has been licensed for human use, and special challenges arise in 
developing vaccines for diseases that almost exclusively affect immune compromised 
individuals. While some live attenuated fungal strains induce protective immunity in mice 
[81], caution needs to be exercised that such strains are sufficiently attenuated so as not to 
cause disease in persons with impaired immunity. Killed strains obviate this concern but 
autoimmune and inflammatory reactions to vaccine components need to be carefully 
monitored. For example, a formalin-killed Coccidioides spherule whole cell vaccine 
targeting individuals at risk for the endemic mycosis coccidioidomycosis showed a trend 
towards protection but was poorly tolerated [82].
One strategy for fungal vaccines is utilization of conserved fungal cell wall components to 
stimulate adaptive immunity. This strategy has the potential for eliciting protective 
antibodies against multiple genera of fungi. While cell wall glycans are poorly 
immunogenic, glycan conjugate vaccines effectively induce adaptive responses [83]. A 
glycoconjugate vaccine consisting of brown algae β-glucan covalently linked to diphtheria 
toxin protects against challenge with multiple fungi in animal models [84], and similar 
approaches have been used to develop protective antibodies against capsular components of 
C. neoformans [85].
Due to their capacity to be innately recognized by the host immune system, fungal cell wall 
glycans (β-glucans, mannans and chitiosan) have been utilized as antigen delivery systems 
and adjuvants [83]. The benefits of this technique have been demonstrated in murine 
experiments where encapsulation of antigen in β-glucan particles resulted in durable 
antigen-specific Th1 and Th17 T-cell and antibody responses [86,87]. Dendritic cell (DC) 
vaccination is another potentially beneficial approach and in murine models of HSCT 
associated aspergillosis, this resulted in improved antigen-specific Th1 responses, 
accelerated lymphoid and myeloid cell recovery, and improved survival following infective 
challenge [88].
An active area of investigation is the identification of immunoreactive fungal antigens that 
can be used in subunit vaccines. Although many antigens are species- or genus-specific and 
would elicit protective responses against only a narrow range of fungal pathogens, this 
approach may have merit in targeted at-risk populations. For example, a vaccine consisting 
of a recombinant N-terminus of Als3 protein (required by Candida for endothelial 
adherence) has been shown to induce antigen-specific antibody, Th1 and Th17 T-lymphocyte 
responses, and reduce fungal burden in hematogenously challenged mice [89].
Phase I trials have shown it to be safe and immunogenic in healthy adults [90], and a clinical 
trial of this vaccine in women with recurrent vulvovaginal candidiasis recently completed 
enrolment [91].
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IMMUNE SUPPRESSIVE THERAPY
Finally, although the majority of evidence for immune modulation in IFI favours techniques 
that stimulate the immune response, in some fungal infections inhibition of an overly 
exuberant response may be preferential. In patients with HIV-associated Pneumocystis 
jirovecii pneumonia (PCP), adjunctive corticosteroids reduce IL-8 driven neutrophil 
pulmonary infiltration and decrease patient mortality in severe disease [92,93]. 
Corticosteroids may also reduce the incidence of cerebrovascular events in Coccidioides 
immitis meningitis [94] and beneficial effects have been reported in individual patients with 
chronic disseminated (hepatosplenic) candidiasis and in cryptococcal meningitis-IRIS 
[7,17]. However, the use of corticosteroids in patients with HIV-associated cryptococcal 
meningitis who do not have IRIS is not recommended after a clinical trial demonstrated 
slower clearance of infection and worse clinical outcome [95]. This is consistent with 
immunological studies that demonstrate an association between a poor inflammatory 
response in the CSF and blood, and increased disease severity and mortality [96,97].
FUTURE DIRECTIONS
The pathogenesis of fungal infections is instrinsically linked to host immune response. 
Given the recent advances in immune therapy against cancer, the prospect of modulating the 
host immune response in fungal infections is appealing but thus far elusive. Many techniques 
have shown great promise in vitro and in animal models but very few have been tested, much 
less proven to work, in patients. Future research should concentrate on translating promising 
ideas such as adoptive T cell transfer and adjunctive IFN-γ therapy to the clinic and 
developing immune assays to identify groups of patients likely to benefit.
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HIGHLIGHTS
• Pro-inflammatory cytokine therapy confers benefit in animal models of 
mycoses
• Translation of pre-clinical findings into patient therapy is limited to date
• IFN-gamma therapy in humans results in faster clearance of Cryptococcus
• Antigen-specific T cell therapies are promising but technically challenging
• Results of anti-Candida vaccine trials are awaited
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Figure 1. Mechanisms of adoptive T-cell generation
Therapeutic fungal-specific T-cells can be generated through PBMC exposure to fungal 
antigen, identification of fungal-specific T-cells (e.g. immunomagnetic sorting), and T-cell 
expansion or through generation of CAR T-cells with expression of antibodies containing 
extracellular fungal recognition component (e.g. Dectin-1). CAR– chimeric antigen receptor; 
PBMC – peripheral blood mononuclear cells; PRR – pattern recognition receptor
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Table 1
A summary of evidence supporting different immunomodulatory strategies in three main 
invasive fungal infections
Shading indicates level of evidence: green – cell culture or animal experiments; orange – animal models and 
exploratory human studies; red – animal models and human clinical trials.
Aspergillus Candida Cryptococcus
G-CSF Enhanced protection & 
antifungal response in animal 
models [22,23]
Enhanced protection and antifungal 
response in animal models [21]. Faster 
resolution of infection in human trials 
[25].
GM-CSF Reduction in tissue burden in 
experimental infection [29]
Resolution of fluconazole-refractory 
oropharyngeal candidiasis in 7 out of 
11 AIDS patients [35]
Enhanced response to antifungal 
therapy in cell culture models 
[30]. Persons with anti-GM-CSF 
autoantibodies at risk of infection 
[31]
M-CSF Enhanced protection in 
neutropenic animal models [39]
IFN-γ Enhanced protection and 
antifungal response in animal 
models [47,48].
Increased susceptibility and mortality 
in knockout mice [41].
Increased susceptibility in IFN-γ 
deficienty/inhibition [42,46]. 
Exogenous IFN-γ results in 
reduced mortality in animal 
models [51] and faster clearance 
in human trials [53].
PD-1 blockade Improved T cell responses and 
survival in mice [71]
mAb Improves protection in animal 
model [75].
mAb to hsp-90 protect mice from 
infection [74]and associated with 
faster clearance in clinical trials [77]
Enhanced protection and animal 
fungal response in animal models 
[73,79]. Reduction in antigen titre 
in human pilot studies [78]
Granulocyte transfusion Animal model demonstrate 
benefits of posaconazole-loaded 
leukocytes transfusion[61]
Better than expected outcome in 
human pilot studies [58].
T cell transfusion Prolonged survival in animal 
models [65,69].
No complications in human pilot 
studies [66]
Vaccination Improved survival with dendritic 
cell vaccine in mice [88]
New vaccines confer protection in 
animal models [84,89], and are 
immunogenic and safe in humans; 
clinical trials have recently completed 
enrolment [90,91].
Glycoprotein and glucan particle 
vaccine provide protection in 
animal models [85,87].
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